Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 629

1.

Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective.

Collins N, Tighe AP, Brunton SA, Kris-Etherton PM.

J Am Coll Nutr. 2008 Dec;27(6):659-66. Review.

PMID:
19155425
2.

Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids.

Brunton S, Collins N.

Curr Med Res Opin. 2007 May;23(5):1139-45. Review. Erratum in: Curr Med Res Opin. 2008 Jan;24(1):247.

PMID:
17519081
3.
4.

PUFA for human health: diet or supplementation?

Abete P, Testa G, Galizia G, Della-Morte D, Cacciatore F, Rengo F.

Curr Pharm Des. 2009;15(36):4186-90. Review.

PMID:
20041820
5.
6.

Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.

McKenney JM, Sica D.

Pharmacotherapy. 2007 May;27(5):715-28. Review.

PMID:
17461707
7.

The impact of cGMP compliance on consumer confidence in dietary supplement products.

Crowley R, FitzGerald LH.

Toxicology. 2006 Apr 3;221(1):9-16. Epub 2006 Feb 15.

PMID:
16469425
8.

Patient use of dietary supplements: a clinician's perspective.

Sadovsky R, Collins N, Tighe AP, Brunton SA, Safeer R.

Curr Med Res Opin. 2008 Apr;24(4):1209-16. doi: 10.1185/030079908X280743 . Epub 2008 Mar 17. Review.

PMID:
18348745
9.
10.

FDA regulation of dietary supplements and requirements regarding adverse event reporting.

Frankos VH, Street DA, O'Neill RK.

Clin Pharmacol Ther. 2010 Feb;87(2):239-44. doi: 10.1038/clpt.2009.263. Epub 2009 Dec 23.

PMID:
20032973
11.

Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.

Fialkow J.

Am J Cardiovasc Drugs. 2016 Aug;16(4):229-39. doi: 10.1007/s40256-016-0170-7. Review.

12.

How physicians should evaluate dietary supplements.

Glisson JK, Walker LA.

Am J Med. 2010 Jul;123(7):577-82. doi: 10.1016/j.amjmed.2009.10.017. Epub 2010 May 20. Review.

PMID:
20493463
13.

Dispelling the myths about omega-3 fatty acids.

Sadovsky R, Collins N, Tighe AP, Safeer RS, Morris CM, Brunton SA.

Postgrad Med. 2008 Jul;120(2):92-100. doi: 10.3810/pgm.2008.07.1796. Review.

PMID:
18654074
14.

Compounding botanicals: a legal perspective.

Valentino JG, Bormel FG.

J Am Pharm Assoc (Wash). 1999 Jul-Aug;39(4):537-44.

PMID:
10467820
15.

The regulation of dietary supplements.

Larsen LL, Berry JA.

J Am Acad Nurse Pract. 2003 Sep;15(9):410-4. Review.

PMID:
14560437
16.

Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.

Bays HE, Tighe AP, Sadovsky R, Davidson MH.

Expert Rev Cardiovasc Ther. 2008 Mar;6(3):391-409. doi: 10.1586/14779072.6.3.391. Review.

PMID:
18327998
17.

FDA's review of scientific evidence for health claims.

Schneeman B.

J Nutr. 2007 Feb;137(2):493-4.

18.
19.

Marketing dietary supplements in the United States: a review of the requirements for new dietary ingredients.

Noonan C, Patrick Noonan W.

Toxicology. 2006 Apr 3;221(1):4-8. Epub 2006 Feb 21. Review.

PMID:
16497425
20.

Dietary supplements: how they are used and regulated.

Hathcock J.

J Nutr. 2001 Mar;131(3s):1114S-7S. Review.

Supplemental Content

Support Center